Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-24-235952
Filing Date
2024-10-10
Accepted
2024-10-10 16:30:59
Documents
2
Group Members
ABINGWORTH BIOVENTURES 8 LPABINGWORTH LLPCARLYLE GENESIS UK LLCCARLYLE HOLDINGS I GP INC.CARLYLE HOLDINGS I GP SUB L.L.C.CARLYLE HOLDINGS I L.P.CARLYLE INVESTMENT MANAGEMENT L.L.C.CG SUBSIDIARY HOLDINGS L.L.C.TC GROUP, L.L.C.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d889611dsc13da.htm SC 13D/A 188995
2 EX-99.6 d889611dex996.htm EX-99.6 11819
  Complete submission text file 0001193125-24-235952.txt   203094
Mailing Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Business Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004 202 729 5626
Carlyle Group Inc. (Filed by) CIK: 0001527166 (see all company filings)

EIN.: 452832612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice
(CF Office: 02 Finance)

Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Subject) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92480 | Film No.: 241365556
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)